CTRI/2022/03/041049招募中3 期
A single arm open labeled study to evaluate the effect of Nethika Naturals Womens care supplement in irregular menstruation w.s.r.t. oligomenorrhea
ethika Naturals Pvt Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Women between 14 to 55 years of age
- •2.Suffering from oligomenorrhea for at least 3 months
- •3.Patients willing to sign written authorization to provide data for the study
排除标准
- •1.Patients having vaginal bleeding of unknown etiology
- •2.Patients taking oral contraceptives
- •3.Pregnant and lactating patients
- •4.Patients with history of liver disease, porphyria or depression.
- •5.Patients not willing to sign written authorization for data release consent form
研究者
相似试验
尚未招募
3 期
A Study to evaluate the effect of Siddharthakavachadi Cream in AcneCTRI/2022/09/045166DR PRATHIBHA G
进行中（未招募）
1 期
A Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients with Early Stage Relapsing Remitting Multiple SclerosisRelapsing remitting multiple sclerosis (RRMS)MedDRA version: 20.1Level: PTClassification code 10028245Term: Multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 21.1Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: PTClassification code 10048393Term: Multiple sclerosis relapseSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.1Level: LLTClassification code 10039720Term: Sclerosis multipleSystem Organ Class: 10029205 - Nervous system disordersEUCTR2016-002937-31-GBF. Hoffmann-La Roche Ltd1,225
进行中（未招募）
1 期
A Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients with Early Stage Relapsing Remitting Multiple SclerosisRelapsing remitting multiple sclerosis (RRMS)MedDRA version: 20.1Level: PTClassification code 10028245Term: Multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 21.1Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: PTClassification code 10048393Term: Multiple sclerosis relapseSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.1Level: LLTClassification code 10039720Term: Sclerosis multipleSystem Organ Class: 10029205 - Nervous system disordersEUCTR2016-002937-31-SKF. Hoffmann-La Roche Ltd1,225
进行中（未招募）
1 期
A Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients with Early Stage Relapsing Remitting Multiple SclerosisEUCTR2016-002937-31-BGF. Hoffmann-La Roche Ltd1,225
进行中（未招募）
1 期
A Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Early Stage Relapsing Remitting Multiple SclerosisEUCTR2016-002937-31-PLF. Hoffmann-La Roche Ltd1,225